

# Enzymatic Therapy

NATURAL MEDICINES®

November 12, 2003

Office of Nutritional Products, Labeling &  
Dietary Supplements, HFS 810  
Center for Food Safety and Applied Nutrition  
Food and Drug Administration  
5100 Paint Branch Parkway  
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDIENT(S) TO WHICH THE CLAIM REFERS</u>
Vitaline® L-Carnitine	L-Carnitine is a natural substance whose primary function is to carry long-chain fatty acids into the mitochondria, the powerhouses of every cell.* Fatty acids are utilized as fuel for energy production in most tissues of the body.* L-Carnitine has also been found to support dopaminergic neurotransmitters.*	L-Carnitine USP

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 11/12/03

825 Challenger Drive  
Green Bay, WI 54311-8328  
Ph: 920-469-1313  
Fax: 888-570-6460  
www.enzy.com

975 0162


LET

13412

Vitaline L-Carnitine 9c

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

A handwritten signature in black ink that reads "Michael P. Devereux". The signature is written in a cursive style with a large, stylized initial "M".

Michael P. Devereux  
Chief Financial Officer